JP2015503608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503608A5 JP2015503608A5 JP2014551706A JP2014551706A JP2015503608A5 JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5 JP 2014551706 A JP2014551706 A JP 2014551706A JP 2014551706 A JP2014551706 A JP 2014551706A JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rnai agent
- beta
- composition
- catenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 108091030071 RNAI Proteins 0.000 claims 18
- 230000009368 gene silencing by RNA Effects 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 102000015735 Beta-catenin Human genes 0.000 claims 11
- 108060000903 Beta-catenin Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 108010067316 Catenins Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000010932 epithelial neoplasm Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- -1 Epi-Freedelanol Natural products 0.000 claims 2
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 229920001218 Pullulan Polymers 0.000 claims 2
- 239000004373 Pullulan Substances 0.000 claims 2
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims 2
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 claims 2
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 2
- 229920005615 natural polymer Polymers 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 235000019423 pullulan Nutrition 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 125000006853 reporter group Chemical group 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 150000003648 triterpenes Chemical class 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584530P | 2012-01-09 | 2012-01-09 | |
| US61/584,530 | 2012-01-09 | ||
| US201261598530P | 2012-02-14 | 2012-02-14 | |
| US61/598,530 | 2012-02-14 | ||
| PCT/IB2013/050159 WO2013105022A2 (en) | 2012-01-09 | 2013-01-08 | Organic compositions to treat beta-catenin-related diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503608A JP2015503608A (ja) | 2015-02-02 |
| JP2015503608A5 true JP2015503608A5 (enExample) | 2016-03-03 |
| JP6158833B2 JP6158833B2 (ja) | 2017-07-05 |
Family
ID=47720548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551706A Active JP6158833B2 (ja) | 2012-01-09 | 2013-01-08 | ベータ−カテニン関連疾患を処置するための有機組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10023862B2 (enExample) |
| EP (1) | EP2802658A2 (enExample) |
| JP (1) | JP6158833B2 (enExample) |
| CN (1) | CN104302768A (enExample) |
| AU (1) | AU2013208720A1 (enExample) |
| BR (1) | BR112014016870A2 (enExample) |
| CA (1) | CA2860676A1 (enExample) |
| HK (1) | HK1205758A1 (enExample) |
| WO (1) | WO2013105022A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3134527B1 (en) * | 2014-04-22 | 2018-12-12 | Medizinische Hochschule Hannover | Lncrnas for therapy and diagnosis of angiogenesis |
| AU2017232496B2 (en) * | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| US11185553B2 (en) * | 2016-10-31 | 2021-11-30 | Samsung Life Public Welfare Foundation | Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| AU2019222767A1 (en) * | 2018-02-14 | 2020-08-27 | Deep Genomics Incorporated | Oligonucleotide therapy for Wilson disease |
| CN111500694B (zh) * | 2019-01-31 | 2023-02-24 | 中国科学院脑科学与智能技术卓越创新中心 | Baz2b基因作为靶点在缓解衰老中的应用 |
| TW202130809A (zh) * | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
| US20240082272A1 (en) | 2020-12-09 | 2024-03-14 | The Regents Of The University Of Michigan | Compositions and methods for treating wnt-driven cancer |
| WO2022187263A2 (en) * | 2021-03-01 | 2022-09-09 | Steadman Philippon Research Institute | Mcm for gene therapy to activate wnt pathway |
| AU2022316139A1 (en) * | 2021-07-23 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
| WO2025090541A1 (en) * | 2023-10-25 | 2025-05-01 | The Regents Of The University Of California | Covalent degraders of oncogenic transcription factors |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| ES2374290T3 (es) | 1998-03-20 | 2012-02-15 | Commonwealth Scientific And Industrial Research Organisation | Genes sintéticos y constructos genéticos que comprenden los mismos. |
| CA2346448A1 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| KR20020030780A (ko) | 1999-07-09 | 2002-04-25 | 이곤 이 버그 | 플라스미드 서열의 전사 동안 비정상적인 ｒｎａ 형성을예방하기 위한 방법 및 조성물 |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| JP2003527856A (ja) | 2000-03-17 | 2003-09-24 | ベニテック オーストラリア リミテッド | 遺伝子のサイレンシング |
| AU2001260140A1 (en) | 2000-03-22 | 2001-10-03 | Avntis Pharma Deutschland Gmbh | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene. |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| ATE513910T1 (de) | 2000-05-30 | 2011-07-15 | Johnson & Johnson Res Pty Ltd | Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| IL153817A0 (en) | 2000-07-19 | 2003-07-31 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| US20030166064A1 (en) | 2000-08-03 | 2003-09-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| AU2002324723B2 (en) | 2001-08-16 | 2007-10-25 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| EP2221377B2 (en) | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| WO2003075836A2 (en) | 2002-03-05 | 2003-09-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| ES2555307T3 (es) | 2002-03-08 | 2015-12-30 | Eisai R&D Management Co., Ltd. | Compuestos macrocíclicos útiles como agentes farmacéuticos |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| AU2003279004B2 (en) | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20040204377A1 (en) | 2002-11-26 | 2004-10-14 | University Of Massachusetts | Delivery of siRNAs |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| KR20160058972A (ko) | 2004-09-02 | 2016-05-25 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| WO2006031977A2 (en) * | 2004-09-13 | 2006-03-23 | The Regents Of The University Of California | Inhibition of pancreatic cancer cell growth |
| AU2006213610B2 (en) | 2005-02-10 | 2012-04-05 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosing and treating cancer using beta-catenin splice variants |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006272837B2 (en) | 2005-07-21 | 2012-08-23 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of MEK |
| US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| US20100105134A1 (en) | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| CA2685444A1 (en) * | 2007-05-01 | 2008-11-06 | Jesper Worm | Rna antagonist compounds for the modulation of beta-catenin |
| BRPI0811170B8 (pt) | 2007-05-22 | 2021-05-25 | Arcturus Therapeutics Inc | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila |
| WO2008156661A2 (en) * | 2007-06-15 | 2008-12-24 | Beth Israel Deaconess Medical Center | BACTERIAL MEDIATED TNF-α GENE SILENCING |
| TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法 |
| CA2701292C (en) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| KR20100089869A (ko) * | 2007-11-05 | 2010-08-12 | 노파르티스 아게 | Ｗｎｔ 활성화의 측정 및 ｗｎｔ-관련 암의 치료를 위한 방법 및 조성물 |
| CA2710713C (en) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| EP2266550A1 (en) * | 2009-06-15 | 2010-12-29 | Institut Curie | Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders |
| CA2677068A1 (en) | 2009-09-01 | 2011-03-01 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| EP2488206B1 (en) | 2009-10-16 | 2018-03-21 | University Health Network (UHN) | Porphyrin nanovesicles |
| KR101605932B1 (ko) | 2009-12-18 | 2016-03-24 | 노파르티스 아게 | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 |
| JP5976643B2 (ja) * | 2010-07-06 | 2016-08-24 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物 |
| US8518907B2 (en) * | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
-
2013
- 2013-01-08 BR BR112014016870A patent/BR112014016870A2/pt not_active IP Right Cessation
- 2013-01-08 WO PCT/IB2013/050159 patent/WO2013105022A2/en not_active Ceased
- 2013-01-08 AU AU2013208720A patent/AU2013208720A1/en not_active Abandoned
- 2013-01-08 EP EP13704633.0A patent/EP2802658A2/en active Pending
- 2013-01-08 US US14/371,131 patent/US10023862B2/en active Active
- 2013-01-08 CA CA2860676A patent/CA2860676A1/en not_active Abandoned
- 2013-01-08 JP JP2014551706A patent/JP6158833B2/ja active Active
- 2013-01-08 HK HK15106407.7A patent/HK1205758A1/xx unknown
- 2013-01-08 CN CN201380013297.9A patent/CN104302768A/zh active Pending
-
2018
- 2018-06-13 US US16/007,517 patent/US20180282728A1/en not_active Abandoned
-
2024
- 2024-11-07 US US18/939,814 patent/US20250270555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503608A5 (enExample) | ||
| JP2014525435A5 (enExample) | ||
| JP2015517466A5 (enExample) | ||
| AU2013208720A1 (en) | RNAi agents to treat Beta-Catenin related diseases | |
| JP2016511256A5 (enExample) | ||
| JP4788774B2 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| Cassidy et al. | Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| Chen et al. | Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin | |
| Deplanque et al. | A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer | |
| Li et al. | Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure | |
| CN107108686B (zh) | 用于恶性肿瘤的rna干扰组合物和方法 | |
| Gao et al. | Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells | |
| NZ741397A (en) | Oligonucleotide compositions and methods thereof | |
| JP2013514321A5 (enExample) | ||
| Roca-Alonso et al. | Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? | |
| Nishimura et al. | Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer | |
| JP2018512060A5 (enExample) | ||
| JP2018536689A5 (enExample) | ||
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| Sun et al. | Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study | |
| JP2013525332A5 (enExample) | ||
| RU2013145551A (ru) | Комбинация олигонуклеотида анти-кластерина с антагонистом рецептора андрогена для лечения рака предстательной железы | |
| Lang et al. | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer |